|| Checking for direct PDF access through Ovid
Management of calcineurin inhibitor (CNI) therapy in kidney transplant recipients may be complicated due to polypharmacy. As CNI undergo extensive metabolism by cytochrome-P450 enzymes (CYP) drug-induced CYP-inhibition poses risk for elevated CNI blood concentrations. Here, we report on two kidney transplant recipients treated with tacrolimus who presented with signs of tacrolimus intoxication at admission.Patient A was started on antiviral medication ombitasvir, paritaprevir, ritonavir and dasabuvir for hepatitis-C virus treatment 3 days prior to hospitalization. And patient B was treated with clarithromycin for pneumonia. Both therapies cause drug-induced CYP-inhibition and both patients displayed highly elevated tacrolimus serum concentrations and acute kidney injury. After application of CYP-inducing agents rifampicin and phenytoin respectively, tacrolimus levels were rapidly reduced and renal function recovered (Table).Treating severe CNI-intoxication is an infrequent yet emergent condition. These results add to the knowledge of therapeutic drug-induced CYP-induction.